SCHEMBL492397

SCHEMBL492397

c1cc2c[nH]nc2cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28675683 0.98
Hydrochloric Acid SCHEMBL3810977 0.98 PIM1 (0.36)
SCHEMBL381051 0.84
SCHEMBL11903654 0.83 IKBKE (0.38)
SCHEMBL5025752 0.83 IKBKE (0.38)
SCHEMBL4048108 0.83 KDM4A (0.41)
Hydrochloric Acid SCHEMBL25221294 0.82 HASPIN (0.37)
Water SCHEMBL27309708 0.82 HASPIN (0.37)
SCHEMBL3233764 0.79 IKBKE (0.38)
SCHEMBL30995281 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568972-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2025-06-18 EP claimed
CN-119654326-A Novel heterocyclic compounds 豪夫迈·罗氏有限公司 2025-03-18 CN claimed
EP-4514784-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE Petra Pharma Corporation (US) 2025-03-05 EP claimed
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION 2024-06-06 US claimed
WO-2024097172-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2024-05-10 WO claimed
EP-4347040-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF CANCER Petra Pharma Corporation (US) 2024-04-10 EP claimed
WO-2024059745-A2 N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ANTAGONISTS AND USES THEREOF BEXSON BIOMEDICAL, INC. (US) 2024-03-21 WO claimed
WO-2024033277-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2024-02-15 WO claimed
US-11878970-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-23 US claimed
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 US claimed
EP-1668014-A2 FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-14 EP claimed
EP-1660427-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2006-05-31 EP claimed
US-20050119295-A1 Fused heterocyclic compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-02 US claimed
WO-2005040169-A2 FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-05-06 WO claimed
WO-2005016862-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORPORATION (JP) 2005-02-24 WO claimed
WO-2004106339-A2 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2004-12-09 WO claimed
EP-1068358-A1 OLIGONUCLEOTIDES CONTAINING PYRAZOLO 3,4-D]PYRIMIDINES FOR HYBRIDIZATION AND MISMATCH DISCRIMINATION Epoch Pharmaceuticals, Inc. (US) 2001-01-17 EP claimed
WO-1999051775-A1 OLIGONUCLEOTIDES CONTAINING PYRAZOLO[3,4-D]PYRIMIDINES FOR HYBRIDIZATION AND MISMATCH DISCRIMINATION EPOCH PHARMACEUTICALS, INC. (US) 1999-10-14 WO claimed
EP-0707585-A1 BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES PFIZER INC. (US) 1996-04-24 EP claimed
WO-1995001980-A1 BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES PFIZER INC. (US) 1995-01-19 WO claimed